Bayer CropScience Limited
Quality (73/100) does the heavy lifting; momentum (15/100) is the drag.
Fair valueOur blended model reads Bayer CropScience Limited as a Sell at 42/100. On 27.3x trailing earnings it sits pricier than the Basic Materials median of about 22.2x. The price is about 31% below its 52-week high of ₹6,160.63 and 4% above the low of ₹4,066.5. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹5,186.83 implies about 22% upside across 6 analysts. It clears 7 of 13 investability checks, with durability 73, valuation 36 and momentum 15 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹2,624.07.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-31.27% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell42Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 23.7%
- Pass: Low debt (D/E < 0.5): 0.03x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 5%
- Pass: Earnings growing: 13%
- Pass: Net margin ≥ 10%: 12.1%
- Pass: Current ratio > 1.5: 1.92
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 6.2
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter71.7%
- Institutions11.6%
- Public & other16.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (23.7%).
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 6.2.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Trades ~23% above our estimated fair value.
About Bayer CropScience Limited
Bayer CropScience Limited manufactures and distributes insecticides, fungicides, herbicides, and hybrid corn seeds across India, Germany, Bangladesh, and other markets. The company also produces pharmaceuticals for cardiology, gynecology, diabetes, oncology, and ophthalmology, alongside medical imaging equipment including CT, X-Ray, and MRI devices, and consumer health products.
Bayer CropScience Limited — frequently asked questions
Is Bayer CropScience Limited a buy, hold or sell?
StocksWizard currently rates Bayer CropScience Limited (BAYERCROP) a Sell, based on a blended score of 42/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Bayer CropScience Limited's fair value?
Our blended DCF and relative-valuation model estimates Bayer CropScience Limited's fair value at about ₹3,280.09, versus a current price of ₹4,234.4 — roughly 23% downside. On that basis the stock looks overvalued by 23%.
Is Bayer CropScience Limited financially healthy?
Bayer CropScience Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Bayer CropScience Limited's share price performed?
Bayer CropScience Limited is down 9% over three months, and last traded at ₹4,234.4. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.